Does Mounjaro help menopausal weight gain?
Quick answer
Mounjaro (tirzepatide) can support weight management for some people who meet prescribing criteria, including during or after menopause. It does not treat menopause or replace hormone therapy, and menopause-specific evidence is limited; discuss suitability and symptoms with a clinician.

Mounjaro can help some people manage weight gained around menopause if they meet the criteria for weight treatment. It does not replace oestrogen or directly treat menopausal symptoms. Evidence supports tirzepatide for weight management generally, but research specifically in menopausal women is more limited, so expectations and treatment need individual review.
Why can weight change around menopause?
Falling oestrogen can shift fat towards the abdomen, while ageing can reduce muscle mass. Hot flushes, poor sleep, pain, mood changes and caring responsibilities can make eating and movement harder. These are biological and practical pressures, not a failure of willpower. Not every new symptom or weight change should automatically be attributed to menopause.
How might Mounjaro help?
Tirzepatide, the ingredient in Mounjaro, activates receptors for two gut hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), involved in appetite and blood sugar control. It can reduce hunger and help people feel full sooner. It is prescribed for recognised diabetes or weight-management indications, not simply because someone is menopausal. UK licence criteria and NHS access rules are not identical.
What does menopause-specific research show?
General weight-management trials support tirzepatide, but do not establish that it reverses the hormonal changes of menopause. A small observational study reported at ENDO 2025 found different weight outcomes in women using tirzepatide with or without menopause hormone therapy. Treatment was not randomly assigned, so differences in the participants or their care could explain some findings. It is not a reason to start hormone replacement therapy, or HRT, solely to increase weight loss.
Can it be used alongside HRT?
HRT and weight treatment address different needs. A clinician should review menopausal symptoms, bleeding, cardiovascular and bone health, and the suitability of each medicine. HRT is not contraception. If you take oral HRT, ask your menopause clinician to review the regimen, particularly the progestogen needed to protect the womb lining when you have a uterus. Vomiting and delayed stomach emptying may affect oral treatment; do not change doses or omit progestogen without advice. The established oral-contraception warning should not be assumed to prove an identical interaction with HRT.
What support and safety checks matter?
Include protein-containing foods, enough overall nourishment and strength activity adapted to your ability to protect muscle. Review persistent nausea, poor intake or dehydration before increasing treatment. Severe persistent abdominal pain, especially extending to the back, needs urgent assessment for pancreatitis, inflammation of the pancreas. Bleeding after menopause also needs prompt medical assessment rather than being blamed on medication.
Do pregnancy precautions still apply?
Pregnancy can still occur during perimenopause. MHRA advice is to use effective contraception: with tirzepatide, switch from the pill to a non-oral method or add a barrier method for four weeks after starting and four weeks after every dose increase. Stop tirzepatide at least one month before trying to conceive. If pregnancy occurs, stop it and contact your prescriber promptly. See the related menopause condition information rather than treating medication as a substitute for assessment.
Sources & further reading

Reviewed by
Dr Chinnadorai Rajeswaran
Specialist Endocrinologist · MBBS MRCP FRCP
Last Reviewed: November 2026
Read about menopause and related care.


